Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Naseem Eisa, Omar Barood
https://pubmed.ncbi.nlm.nih.gov/41877354/Actively Recruiting
Led by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Updated on 2026-09-25
200
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are studying adults with obesity andor type 2 diabetes who start treatment with GLP-1 receptor agonist medications, which are approved for weight loss and blood sugar control. The study aims to understand how muscle and fat in the body change over about one year after starting these medications, focusing on the quality of weight loss and its impact on strength and daily function. This is an observational study following patients under real-world medical care without assigning treatments. Participants will be adults beginning or adjusting doses of GLP-1 receptor agonists as part of their usual care. They will be followed for 52 weeks with visits at baseline, 24 weeks, and 52 weeks, plus a phone check-in at 12 weeks. Assessments include body composition scans using DXA, grip strength, walking speed, physical performance tests, blood tests, and questionnaires on diet and physical activity. Some participants may opt to provide an extra blood sample for genetic testing. During the study, participants will have body composition measured, physical function tested, and blood samples collected to track changes in muscle, fat, metabolic markers, and other health indicators. The study also monitors treatment adherence and changes in medication use. Data are collected at two centers in Mexico using secure electronic systems to protect confidentiality. The study does not involve experimental drugs, randomization, or additional costs to participants.
CONDITIONS
Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 52 weeks
Participants are observed while receiving GLP-1 receptor agonist treatment as part of their usual care. They undergo assessments including body composition scans, physical function tests, blood draws, and questionnaires at baseline, 24 weeks, and 52 weeks, with a phone check-in at 12 weeks.
1 baseline visit, 1 phone check-in at 12 weeks, 2 follow-up visits at 24 and 52 weeks
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Naseem Eisa, Omar Barood
https://pubmed.ncbi.nlm.nih.gov/41877354/Alfredo Vozza, Domenico Triggiani, Margherita Fanelli...
https://pubmed.ncbi.nlm.nih.gov/41079186/Clifford J Rosen, Julie R Ingelfinger
https://pubmed.ncbi.nlm.nih.gov/41931049/Rory J McCrimmon, Andrei-Mircea Catarig, Juan P Frias...
https://pubmed.ncbi.nlm.nih.gov/31897524/American Diabetes Association Professional Practice Committee for Diabetes*
https://pubmed.ncbi.nlm.nih.gov/41358900/Wenjia Yang, Han Wu, Xiaoling Cai...
https://pubmed.ncbi.nlm.nih.gov/38346789/Liyun He, Jialu Wang, Fan Ping...
https://pubmed.ncbi.nlm.nih.gov/35344001/Muhammad Shahzeb Khan, Muhammad Hamza Dawood, Yehuda Handelsman...
https://pubmed.ncbi.nlm.nih.gov/41914150/Qiaojuan Jane Su, James R Ashenhurst, Wanwan Xu...
https://pubmed.ncbi.nlm.nih.gov/41951734/Patrick P Gleason, Benjamin Y Urick, Landon Z Marshall...
https://pubmed.ncbi.nlm.nih.gov/38717042/Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead Sponsor